Monthly Archives: May 2016

Inflamax Research selected to join Ontario Premier Kathleen Wynne’s trade mission to Israel


Inflamax Research Inc. is pleased to announce its participation in the upcoming trade mission to Israel organized as part of a provincial governmental initiative by Premier Wynne. Inflamax Research will aid in establishing Ontario as a leading knowledge economy partner and investment destination by forging new global connections with innovation leaders.

“As one of the Ontario businesses invited to be part of the delegation, we are eager to forge new global partnerships with other top innovators in the life sciences field,” announced Dr. Piyush Patel, CEO of Inflamax Research.

Israel is a significant research and development hub in the global development of medications and devices and therefore forms a significant market potential for Inflamax Research, a Contract Research Organization (CRO) which specializes in innovative drug and device development for the treatment of disease. During the mission, Inflamax Research will have many meetings with drug developers such as Teva Israel, a leader in global healthcare innovations.

While in Israel, Dr. Patel and Dr. Salapatek (Inflamax’s President & Chief Science Officer), will be participating in a signing ceremony with Dr. Alon Harris and Dr. Ra’anan Gefen from AdOm Tech, Israel. This Memorandum of Understanding (MOU) marks the commencement and contracting of the research program for development of AdOm Tech’s innovative Tear Film Imaging (TFI) device.

“Inflamax is excited to embark on this research together with our collaborators AdOm Tech. The TFI device bodes the potential to provide meaningful insights into the health of the human tear film,” said Dr. Salapatek.

Inflamax is a full-service, global Clinical Research Organization specializing in allergy, ocular, and respiratory diseases, led by world-renown, key-opinion leaders. Inflamax was recently selected as one of Canada’s 50 Best Managed Companies. Inflamax is experienced in the conduct of large single and multi-centre trials using their innovative fixed and mobile Environmental Exposure Chambers and direct instillation models from a study’s concept to protocol writing, site management, data management, and medical writing. Inflamax’s scientists and clinicians are well known to regulatory authorities and regularly participate in an advisory role.